{"filings":[{"id":94835,"accession_number":"0001213900-26-053295","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q1 2026: net loss $1.9M, SYMON-II study at 680 of 750 patients","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $3.7M as of Mar 31, 2026; net loss $1.9M unchanged YoY.","SYMON-II pivotal study enrollment at ~680 patients toward target of 750.","Resolved manufacturing issues with Sanyoseiko; progressing toward analytical/clinical validation.","Continuing FDA 510(k) strategy for Symphony IL-6 test after validation activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94834,"accession_number":"0001213900-26-040728","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial","event_type":"other_material","confidence":"high","bullets":["SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.","Enrollment completion expected within 2-3 months, subject to site activity and patient flow.","Inclusion and exclusion criteria have not caused significant patient exclusions, per CEO Neil Dey."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107496,"accession_number":"0001213900-26-029261","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics raises $125,000 in private placement to insiders at $2.00/share","event_type":"other_material","confidence":"high","bullets":["Issued 62,500 shares of common stock at $2.00 per share to five insiders, including CEO Neil Dey and Chair Donald Chase.","Gross proceeds of $125,000; sale closed on March 17, 2026, under Section 4(a)(2)/Reg D exemption.","No registration rights were granted; shares are restricted securities.","Proceeds likely used for general working capital; no other material terms disclosed.","All purchasers represented as accredited investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107495,"accession_number":"0001213900-26-027890","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay acknowledges NorthStrive's acquisition suggestion, reiterates focus on Symphony platform","event_type":"other","confidence":"high","bullets":["Responds to NorthStrive Fund II LP letter proposing acquisition of Phase-1-ready chronic cough therapeutic program.","Board and management will evaluate the opportunity but emphasize current priorities: Symphony platform, SYMON II study, FDA submission.","Notes NorthStrive did not identify the potential counterparty; requests additional diligence information if available.","Reaffirms commitment to fiduciary duties under Delaware law and preserving cash resources."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107494,"accession_number":"0001213900-26-026749","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay announces Symphony IL-6 Test abstract accepted for SAEM 2026 meeting","event_type":"other_material","confidence":"high","bullets":["Abstract accepted for presentation at Society of Academic Emergency Medicine Annual Meeting, May 18-21, 2026 in Atlanta.","Presentation reports SYMON-I pilot study data: IL-6 levels in ED linked to organ dysfunction (SOFA scores) in sepsis patients.","Principal investigator Nathan Shapiro: IL-6 measured in ED may be associated with subsequent organ dysfunction.","Ongoing SYMON-II pivotal study to validate IL-6 as prognostic biomarker for mortality, to support FDA 510(k) submission.","Company developing rapid near-patient Symphony IL-6 Test for sepsis triage and monitoring."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107493,"accession_number":"0001213900-26-024352","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital","event_type":"other_material","confidence":"high","bullets":["Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.","About 972,000 shares outstanding after full exercise of prefunded warrants; outstanding cash-exercisable warrants with strike above market.","SYMON II clinical study for IL-6 sepsis test progressing; data to support regulatory submission; limited disclosure before submission.","Manufacturing scale-up and supply-chain initiatives on track for commercialization readiness.","Company expects to need at least $20M additional capital through end of FY2027, to be raised in tranches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107492,"accession_number":"0001213900-26-018638","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics: All prefunded warrants exercised; ~972K shares outstanding; 1.5M warrants at $7+","event_type":"other_material","confidence":"high","bullets":["All prefunded warrants from Oct 2025 private placement fully exercised as of Feb 19, 2026.","Common shares outstanding now ~972,000; no remaining prefunded warrants of any class.","Cash-exercisable warrants for ~1.5M shares outstanding, exercise price $7.00 or greater.","Notes recent 13G filings may not reflect 1-for-4 reverse split (Jan 29, 2026), overstating beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107491,"accession_number":"0001213900-26-017641","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations","event_type":"other_material","confidence":"high","bullets":["Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.","Completed monoclonal and polyclonal antibody production, providing capacity for >10 million test cartridges.","Manufacturing readiness includes cartridge characterization for U.S. commercial production and ongoing fabrication for FDA submission.","Company transitions focus to data analysis, regulatory engagement, and commercialization preparedness in 2026.","Technology transfer activities progress without single point of failure, mitigating scale-up risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107490,"accession_number":"0001213900-26-009792","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["3.03","5.03","5.07","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics implements 1-for-4 reverse stock split effective Jan 29, 2026","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-4 ratio; outstanding shares reduced from ~2,834,133 to ~708,533.","Shares from prefunded warrants reduced from 1,055,000 to 263,750; no fractional shares issued.","Common stock continues trading under symbol 'BJDX' on Nasdaq; new CUSIP 095633608.","Board approved final ratio on Jan 27, 2026; Certificate of Amendment filed with Delaware."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123848,"accession_number":"0001213900-25-126358","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-12-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics completes commercial-scale IL-6 antibody production for Symphony cartridges","event_type":"other_material","confidence":"high","bullets":["Completed commercial-scale production of polyclonal and monoclonal anti-IL-6 antibodies meeting internal performance criteria.","Antibodies intended for Symphony cartridge manufacturing for clinical and potential future commercial applications.","Sufficient material to support production of over 9 million Symphony cartridges; additional capacity established.","Symphony System remains under development, subject to further validation and FDA clearance before marketing.","Monoclonal antibodies designated as detection antibodies showed acceptable binding, specificity, and signal performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123847,"accession_number":"0001213900-25-108192","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027","event_type":"other_material","confidence":"high","bullets":["Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.","SYMON-II pivotal trial patient enrollment ~50% completed; sample testing expected late 2026 subject to financing.","Company expects to need at least $20M additional capital by end of FY2027 to fund operations and FDA submission.","Amended agreements with SanyoSeiko to expand manufacturing role for Symphony platform commercialization.","No revenue reported; pre-commercial stage; Symphony IL-6 test targets sepsis diagnostics, market projected at $1.8B by 2030."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123846,"accession_number":"0001213900-25-098281","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics raises $4.5M in private placement of stock and warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.5M; net proceeds ~$4.0M after 8% placement agent fee and expenses.","Issued 2.25M shares/pre-funded warrants at $2.00/unit plus Series F warrants for 4.5M shares at $1.75.","Net proceeds to fund FDA approval efforts, clinical studies, R&D, and working capital.","Rodman & Renshaw acted as exclusive placement agent; warrants include 4.99%/9.99% beneficial ownership caps.","Company agreed to file resale registration statement by Oct 24, 2025, and has 90-day issuance lock-up post-effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123845,"accession_number":"0001213900-25-097564","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Bluejay expands SanyoSeiko partnership for Symphony platform commercialization","event_type":"other_material","confidence":"medium","bullets":["SanyoSeiko will serve as contract manufacturing organization for analyzers, cartridges, and components.","SanyoSeiko to oversee fulfillment, kit assembly, labeling, packaging, shipping, and quality control.","Partnership includes manufacturing redevelopment, raw material sourcing, vendor compliance, and regulatory support.","Bluejay's Symphony platform is a near-patient testing system for biomarkers like IL-6 in sepsis management.","No financial terms disclosed; Symphony not yet FDA cleared."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140514,"accession_number":"0001213900-25-077600","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Bluejay Diagnostics announces Board chair and committee chair changes","event_type":"leadership","confidence":"high","bullets":["Donald R. Chase appointed Chairperson of the Board, succeeding Douglas C. Wurth.","Douglas C. Wurth appointed Chairperson of Nominating and Corporate Governance Committee, succeeding Fred S. Zeidman.","Fred S. Zeidman appointed Chairperson of Compensation Committee, succeeding Donald R. Chase.","Chase remains Audit Committee Chair; all three independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140513,"accession_number":"0001213900-25-073870","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027","event_type":"other_material","confidence":"high","bullets":["SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.","Raised $3.85M in April 2025 warrant inducement financing; anticipates more capital through 2027.","Amended Toray license extends cartridge manufacturing timeline to October 2026.","SanyoSeiko engaged as CMO for Symphony analyzer; cartridge redevelopment via FDA-registered CMO.","No detailed financial results disclosed; company pre-revenue with clinical and operational progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140512,"accession_number":"0001213900-25-068296","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Bluejay extends alternative manufacturing deadline by one year, pays $71k for final chip supply","event_type":"other_material","confidence":"high","bullets":["Deadline to establish alternative manufacturing site for Symphony cartridges extended from Oct 2025 to Oct 2026.","Toray confirms all know-how provided; no further technical assistance obligations.","Bluejay to pay $71,212 to Toray for final supply of certain chip components.","Supply Agreement with Toray remains set to expire on October 23, 2025.","Failure to pay the $71k constitutes material breach; Toray may terminate license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158216,"accession_number":"0001213900-25-055724","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Bluejay Diagnostics shareholders approve reverse stock split of up to 1-for-20","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Chase, N. Dey, S. Dey, Wurth, Zeidman to 2026 term.","Approved reverse stock split at 1-for-2 to 1-for-20 ratio; board may implement within one year.","Approved additional reverse split (same ratio) contingent on first split being executed.","Ratified Wolf & Company as independent auditor for FY 2025.","Record date May 15, 2025; 616,134 shares voted from 1,494,182 outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158215,"accession_number":"0001213900-25-050913","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding","event_type":"other_material","confidence":"high","bullets":["SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.","Cash & equivalents $5.7M as of April 30, 2025; Q1 2025 net loss $1.9M, FY2024 net loss $7.7M.","April 2025 private placement raised $3.8M gross; company aims to raise at least $30M total through FY2027.","Workforce reduced to 5 employees after CTO departure; cost-saving measures implemented.","Annual meeting June 18, 2025: board to shrink from 6 to 5, reverse stock split proposals to maintain Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158214,"accession_number":"0001213900-25-048343","cik":1704287,"company_name":"Bluejay Diagnostics, Inc.","ticker":"BJDX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Bluejay Diagnostics CTO Jason Cook to depart on May 30; severance of 6 months salary plus pro rata bonus","event_type":"leadership","confidence":"high","bullets":["CTO Jason Cook's employment ends May 30, 2025 under separation agreement.","Severance: $120,900 (6 months base salary) plus pro rata 2025 target bonus ($72,540).","Bonus prorated for days employed in 2025; paid in equal installments over 6 months.","Parties may later agree to consulting arrangement on mutually acceptable terms.","Separation treated as termination without cause; Cook retains certain covenants and cooperation obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}